The Global Allergy Diagnostics Market is expected to grow at a CAGR of 10.3% during the forecasting period (2022-2029).
Allergy diagnostics are processes performed in clinical conditions in which a harmless external agent is suspected to have a pathological effect on a human being, thus causing discomfort. The diagnostic procedure for allergies depends on the type of allergens and the mode of transmission. Diagnostic allergy testing in such scenarios is an essential tool for the evaluation of the patient.
The global allergy diagnostics market growth is driven by the rising environmental pollution levels, high incidence of allergic diseases and increasing funds by organizations in allergy diagnostics are anticipated to drive the growth of the allergy diagnostics market.
The rising environmental pollution levels will drive the market growth
Exposure to indoor and outdoor air pollutants, allergens, and occupational exposure are the major risk factors causing chronic respiratory diseases. The prevalence of allergic disorders among the urban population is higher than those living in rural areas due to the higher exposure to environmental pollutants in cities (as a result of vehicular pollution and industrial activities).
As per the WHO, more than 80% of people living in urban areas are exposed to air quality levels that exceed the WHO safety limits; though this is a global trend, its effects are more severe in the urban areas of low-income countries. This is a major indicator for the growth of the allergy diagnostics market, as air pollution from motor vehicles has been indicated as one of the major risk factors responsible for allergic diseases. Epidemiological and toxicological research reveals a causal relationship between air pollution and the increased incidence of asthma, allergic rhinitis, and other allergic disorders. Studies have also demonstrated a significant increase in the incidence and exacerbation of asthma in urban locations with elevated PM 2.5 (particulate matter of size 2.5 micrometers or less), nitrogen dioxide, and ozone concentrations.
Research by allergy/immunology community members has shown that pollutants augment immediate and late-phase responses to allergens. Research also indicates that pollutants contribute to disease development, with tobacco smoke and diesel exhaust particles augmenting primary sensitization to antigens, leading to an IgE response. Epidemiologic studies also demonstrate that exposure to ambient air pollutants contributes to increased hospitalizations, decreased lung growth, and disease development. These factors are driving the growth of the market in the forecast period.
Premium costs associated with allergy diagnostic instruments will hamper the growth of the market
However, several allergy diagnostics instruments, such as luminometers, blot analyzers, scanners, ELISA analyzers, and immunoassay analyzers, are periodically updated by market players. As these instruments are equipped with advanced features and functionalities, they are priced at a premium (the price of each instrument varies based on its accuracy, flexibility, and TAT). For instance, immunoassay analyzers cost between USD 10,000 and USD 20,000, while luminometers cost between USD 3,000 and USD 14,000. Furthermore, maintenance and insurance, laboratory supervision, and overheads are additional expenses required to operate this equipment.
COVID-19 Impact Analysis
The inhaled allergens segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)
Inhaled allergens affect the body when they come in contact with the membranes of the nostrils, throat, or lungs. Pollen is the most common inhaled allergen. Ingested allergens are present in certain foods, such as soy, peanuts, and seafood. The most common allergy symptoms caused by inhaled allergens are itchy eyes, sneezing, watery eyes, etc. The rising pollution in the environment, coupled with the changing lifestyle of the people, is boosting the segment's growth.
The University of South Carolina is working on several inhaled allergens. For instance, it conducted a study on dust mite allergens, which are believed to be among the most potent triggers of asthma. Most mite allergic patients (80%) have IgE antibodies against the mite allergens. These allergens are cysteine proteases, and their proteolytic activity contributes significantly to allergenicity.
The market players adopt various strategies such as product launches, collaborations, acquisitions, and expansions to increase market share. For instance, in December 2018, Hycor Biomedical Inc. received the United States Food and Drug Administration's (FDA) 510(k) clearance for its new allergy testing system, NOVEOS. Thus, the above-mentioned factors are expected to drive segment growth over the forecast period.
North America region holds the largest market share of the global allergy diagnostics market
North America dominates the market for allergy diagnostics and is expected to show a similar trend over the forecast period. Asthma is a major public health concern in Canada. As a lifelong respiratory illness, asthma affects the work productivity, quality of life, mental health, and psychological wellbeing of the Canadian population. In Canada, over 3.8 million individuals had asthma in 2019, as per asthma Canada's 2019 annual asthma survey report. Due to the high incidence of asthma in Canada, it is expected to increase the demand for allergy diagnostics procedures in near future.
Moreover, as per the Global Asthma Network 2018 report, the economic burden of asthma has increased in the United States i.e., total annual asthma costs in the United States increased from USD 60 billion in 2002 to USD 64 billion in 2011. In 2018, annual direct costs per patient in the United States were more than USD 3,000. Due to high death rates associated with asthma and increasing investment in asthma in this country the market is expected to show significant growth in the region.
The allergy diagnostics market is a moderately competitive presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include BioMerieux SA, Danaher Corporation, Showa Denko Materials Co., Ltd. (Hitachi Chemical Diagnostics), and HOB Biotech Group Corp. Ltd, HYCOR Biomedical, Lincoln Diagnostics Inc., Omega Diagnostics Group Plc, Siemens Healthineers AG, Staller genes Greer Ltd, and Thermo Fischer Scientific Inc among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the allergy diagnostics market globally. For instance, in November 2020, Omega Diagnostics received approval from the China National Medical Products Administration (NMPA) for Omega's food detective test in China.
Siemens Healthineers AG
Siemens Healthineers AG is a Germany-based company that supplies technology to the healthcare industry. The Company offers a wide range of products and services in the fields of diagnostic and therapeutic imaging, laboratory and point of care diagnostics, and molecular medicine.
IMMULITE 1000/2000/XPi Immunoassay Systems: Providing multiple tests on a single, easy-to-use analyzer including allergy and a wide range of specialty offerings the IMMULITE® 2000 XPi Immunoassay System makes it simple to scale capabilities without disrupting regular day-to-day operations.
Get your free sample proposal with a single click!